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Conclusions: Baseline post-surgery, pre-radiotherapy cosmesis
is an important determinant of overall cosmesis at 2 years after
radiotherapy. An important component of breast induration and
shrinkage is actually due to surgery rather than radiotherapy. Lar-
ger breast volume, baseline surgical cosmesis, post-operative
infection and smoking influence late radiotherapy toxicity. Modi-
fication of preventable risk factors such as post-operative infec-
tion and smoking may limit the development of late toxicity.
doi:10.1016/j.ejcsup.2010.06.050
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Background: After breast conserving surgery, 90% of recurrent
cancer occurs within the index quadrant. Hence, restricting radi-
ation therapy to the immediate area around the tumour bed after
removal of the primary tumour may be adequate (Vaidya JS et al.
Br J Cancer 1996;74:820–4).
Materials and methods: Using the technique of partial breast
irradiation developed at UCL (Vaidya JS, Baum M, Tobias JS,
et al. Ann Oncol 2001;12:1075–80) we launched the international
TARGIT A randomized controlled trial in March 2000 comparing
the policies of TARGIT versus standard whole breast external
beam radiotherapy (EBRT) after breast conserving surgery with
local recurrence as the main outcome measure (www.thelan-
cet.com/protocol-reviews/99PRT-47). Accrual from 28 interna-
tional centers reached 2232 in April 2010, with 80% power to
detect a difference in relapse rate of 2.5% (the non-inferiority
margin).
Results: Patient demographic and tumour characteristics are as
follows: mean age 63 years (IQR 57–69), mean tumour size 12 mm
(IQR 9–18 mm), N stage 17% +ve. We intend to present the
unblinded data with an analysis of safety and efficacy.
Conclusions: If this analysis shows non-inferiority, then a clin-
ically significant difference in early local recurrence between
TARGIT and EBRT remains unlikely, making single session partial
breast irradiation with TARGITa plausible new standard of care in
the near future.
doi:10.1016/j.ejcsup.2010.06.051
O-51 CLINICAL OUTCOME OF PATIENTS MANAGED IN A DEDI-
CATED PRIMARY BREAST CANCER CLINIC FOR OLDER WOMEN
(THE CLINIC)
K.L. Cheung a, B.M. Syed a, S.J. Johnston a, L. Winterbottomb, H.
Kennedy b, D.A.L. Morgan c. aDivision of Breast Surgery, University of
Nottingham, Nottingham, UK. bNottingham Breast Institute,
Nottingham, UK. cDepartment of Oncology, Nottingham University
Hospitals, Nottingham, UK
Background: The Clinic was established in 1973. Over the last
decade, it has evolved into a combined surgical/oncology facility
supported by dedicated breast care nurses. Also, surgery, with
integral axillary staging, and adjuvant radiotherapy (RT) and sys-
temic therapy have become standard for most patients though
non-operative treatments (e.g. primary endocrine therapy (PET))
are used in others based on multi-disciplinary assessment in
the Clinic. This study aimed to compare the clinical outcome
across these periods.
Methods: Over 36 years (1973–2009), 1708 women P70 years
with early operable primary breast cancer were managed in the
Clinic according to a single set of clinical guidelines at any time
point. Analysis was carried out based on retrospective review
and continued update of patient records.
Results: As at 50-month median follow-up (maximum = 261):
1973–1999 2000–2009
N 917 791
Treatment N (%) N (%)
Surgery 392 (42.7) 446 (56.4)
PET 510 (55.6) 324 (41.0)
Primary RT 9 (1.0) 12 (1.5)
No treatment 6 (0.7) 9 (1.1)
Adjuvant endocrine
therapya
124 (31.7) 247 (55.5)
Adjuvant RTa 15 (6.3) 155 (38.4)
Outcome (% per annum) p-value
Local recurrencea 2.2 0.5 <0.000
Regional recurrencea 1.8 0.4 <0.000
Contralateral cancer 0.7 0.4 0.091
Metastasis 2.9 1.9 <0.002
5-year breast cancer
specific survival
80% 90% <0.000
5-year overall survival 56% 68% <0.000
a Surgery group only.
Conclusion: In this recent decade, while surgery became the
predominant treatment, a significant proportion of patients
(40%) had non-operative therapies, selection of which was
based on assessment in the Clinic. This management approach
appears to produce excellent clinical outcome, which is signifi-
cantly better than earlier period.
doi:10.1016/j.ejcsup.2010.06.052
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Background: The Eurocare-4 (2000–2002) period analysis docu-
ments a mean European age-adjusted 5-year relative breast can-
cer survival of 79% with higher individual figures for Finland
(85.7%), Norway (84.1%) and Sweden (86.3%) (Lancet Oncol
2007;8:784–96). The corresponding mean figure for England was
77.8%. We now compare these predicted survival estimates with
actual age-adjusted relative 5-year breast cancer overall survival
for women diagnosed with invasive breast cancer in the East of
England from 2000 to 2002.
Method: The East of England covers a population of 5.5 million
people. Five-year age-adjusted relative breast cancer survival was
calculated overall, and in specific age groups, for 10,787 women
with invasive breast cancer diagnosed from 2000 to 2002 in the
East of England for comparison with the results from the Euro-
care-4 study.
Results:
Age-adjusted 5-year relative breast cancer survival in East of
England for period 2000–2002.
Age group Number of patients Relative survival 95% CI
45–54 2563 87.5% 86.1–88.9
55–64 2945 89.5% 88.1–90.9
65–74 2335 83.9% 81.8–86.1
75+ 2944 73.3% 70.1–76.4
All women 10,787 82.5% 81.4–83.6
Conclusion: These data confirm breast cancer survival rates for
East of England that are close to European best figures for women
aged 45–64. The mean survival of 82.5% for all women however is
being reduced byworse survival in women aged 65+ and a strategy
that ensuresoptimal breast cancer treatment forwomenin thisage
group should allow the mean survival to improve even further.
doi:10.1016/j.ejcsup.2010.06.053
O-53 A STUDY OF THE VALUE OF COMPREHENSIVE GERIATRIC
ASSESSMENT (CGA) IN OLDER WOMEN WITH PRIMARY BREAST
CANCER – PRELIMINARY RESULTS
L. Hall a, S.W. Tang a, A. Hurria b, L. Winterbottomd, H. Kennedy d,
D.A.L. Morgan e, D. Porock c, K.L. Cheung a. aDivision of Breast
Surgery, University of Nottingham, UK. bCancer and Aging Research
Program, City of Hope, Durate, USA. cSchool of Nursing, University of
Nottingham, UK. dNottingham Breast Institute, Nottingham,
UK. eDepartment of Oncology, Nottingham University Hospitals,
Nottingham, UK
Background: Despite being an important health issue, breast
cancer in older women is under-researched. This study aimed
to identify how CGA may be linked to treatment decision making.
Methods: Women P70 years with newly diagnosed primary
breast cancer in Nottingham were invited to take part. Decision
for a particular treatment was made between the clinical team
and the patient, and this was not part of the study. Each patient
then completed an established CGA tool – a multi-dimensional
questionnaire incorporating information on demographics,
mood, social activities and support, medication, functional sta-
tus, cognition, nutritional state and co-morbidities.
The study is ongoing. At this preliminary analysis, 20 patients
(aged 70–87) were recruited from different treatment groups
(mastectomy n = 8, breast conserving surgery, n = 4, primary
endocrine therapy (PET) n = 7, primary radiotherapy n = 1).
Results: Compared to patients undergoing surgery, the PET
group was found to be older (median age 85 versus 76). Patients
on PET also reported having lower median physical functioning
(7.5 versus 11.5) and social support (66.67 versus 89.95) scores,
mood levels (67.65 versus 85.29) and more co-morbidities (median
4 versus 2).
Conclusions: Using a CGA tool may be beneficial in guiding
treatment decision. This ongoing study may establish a tool spe-
cific to the context of older women with primary breast cancer.
This could then become part of routine consultation and may
help identify patients who would require input of a geriatrician.
When combined with quality of life measures and biological
information, there is potential to provide a holistic approach to
this under-served population.
doi:10.1016/j.ejcsup.2010.06.054
O-54 INVOLVEMENT OF MiR-34A IN RESISTANCE OF BREAST
CANCER CELLS TO DOCETAXEL
Lena Kastl, Andrew C. Schofield. School of Medicine and Dentistry,
University of Aberdeen, UK
Introduction: Understanding the mechanisms of drug resis-
tance is important to improve and deliver effective therapy.
MicroRNAs (miRNA) are small RNA molecules that regulate gene
expression, hence we hypothesised that gene silencing, by altered
miRNA expression, causes docetaxel resistance.
Methods: Quantitative PCR-based miRNA arrays were used to
examine the role ofmiRNAs in acquired resistance of breast cancer
cells (MCF-7 and MDA-MB-231) to docetaxel. Quantitative PCR and
western analysiswere used tomeasure target genemRNAand pro-
teinexpression, respectively.MicroRNAexpressionwasmodulated
and docetaxel response was measured by cell viability assay.
Results: We found 299 and 226 miRNAs altered in MCF-7 and
MDA-MB-231 docetaxel-resistant cells, respectively. Only miRNA
alterations that reached statistical significance, which targeted
experimentally validated genes involved in cell cycle, apoptosis
or drug resistance, were selected for further investigation. Doce-
taxel resistance was associated with increased expression of
miR-34a and miR-141 and decreased expression of miR-7, miR-
16, miR-30a, miR-125a-5p, miR-126 and miR-429. Computational
target prediction revealed 11 candidate genes targeted by these
miRNAs. Quantitative PCR and western analysis confirmed
decreased expression of only two genes, BCL2 and cyclinD1, in
docetaxel-resistant cells, which are both targeted by miR-34a.
Inhibition of miR-34a enhanced response to docetaxel in MCF-7
docetaxel-resistant cells whereas overexpression of miR-34a con-
ferred resistance in MCF-7 docetaxel-sensitive cells. Modulation
of miR-34a expression was correlated with expected BCL2 and
cyclinD1 protein expression changes.
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